February 14, 2025 07:00 PM EST

Lilly’s early bladder cancer data hint at safety edge over J&J’s Balversa

Ayisha Sharma

News Reporter

Eli Lilly has shared first-in-human results for its selective FGFR3 inhibitor in a subset of bladder cancer patients, marking the start of a program that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly’s early bladder cancer data hint at safety edge over J&J’s Balversa

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Healthcare shakeup hits Washington, with cuts at CDC, NIH and other agencies

Exclusive: Drugmakers plan Trump meeting next week amid Washington health shakeups

Kojin Therapeutics shuts down, citing lack of investor interest and complex science

BioNTech vets raise $90M Series A for bispecific I&I startup

ARPA-H chief is out as Trump administration cuts health agencies

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Lil­ly’s ear­ly blad­der can­cer da­ta hint at safe­ty edge over J&J’s Balver­sa

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Lilly’s early bladder cancer data hint at safety edge over J&J’s Balversa